Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Rat TrkA Antibody, R&D Systems™

Goat Polyclonal Antibody has been used in 18 publications
Supplier: R&D Systems AF1056SP
This item is not returnable.
View return policy
Description
TrkA Polyclonal specifically detects TrkA in Rat samples. It is validated for Western Blot, Immunohistochemistry.Specifications
TrkA | |
Polyclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
DKFZp781I14186, EC 2.7.10, EC 2.7.10.1, MTChigh affinity nerve growth factor receptor, Neurotrophic tyrosine kinase receptor type 1, neurotrophic tyrosine kinase, receptor, type 1, NTRK1, NTRK-1, p140-TrkA, TRK1-transforming tyrosine kinase protein, Trk-A, TRKAOncogene TRK, TRKTRK1, tyrosine kinase receptor A | |
Goat | |
Affinity Purified | |
RUO | |
4914 | |
Reconstitute at 0.2 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Western Blot, Immunohistochemistry | |
LYOPH | |
Western Blot 1 ug/mL, Immunohistochemistry 5-15 ug/mL | |
P35739 | |
NTRK1 | |
Mouse myeloma cell line NS0-derived recombinant rat TrkA Ala33-Pro418 Accession # P35739 | |
25 μg | |
Primary | |
Detects rat TrkA in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross-reactivity with recombinant human TrkA and less than 1% cross-reactivity with recombinant mouse (rm) TrkB and rmTrkC is observed. | |
Rat | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction